These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 8375016)

  • 1. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent.
    Patterson LH
    Cancer Metastasis Rev; 1993 Jun; 12(2):119-34. PubMed ID: 8375016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy.
    Patterson LH
    Drug Metab Rev; 2002 Aug; 34(3):581-92. PubMed ID: 12214668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
    Patterson LH; McKeown SR; Robson T; Gallagher R; Raleigh SM; Orr S
    Anticancer Drug Des; 1999 Dec; 14(6):473-86. PubMed ID: 10834269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides.
    Smith PJ; Blunt NJ; Desnoyers R; Giles Y; Patterson LH
    Cancer Chemother Pharmacol; 1997; 39(5):455-61. PubMed ID: 9054961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of AQ4N and its reduction product on radiation-mediated DNA strand breakage.
    Ali MM; Symons MC; Taiwo FA; Patterson LH
    Chem Biol Interact; 1999 Nov; 123(1):1-10. PubMed ID: 10597898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rat cytochromes P450 (CYP) specifically contribute to the reductive bioactivation of AQ4N, an alkylaminoanthraquinone-di-N-oxide anticancer prodrug.
    Raleigh SM; Wanogho E; Burke MD; Patterson LH
    Xenobiotica; 1999 Nov; 29(11):1115-22. PubMed ID: 10598746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells.
    Hejmadi MV; McKeown SR; Friery OP; McIntyre IA; Patterson LH; Hirst DG
    Br J Cancer; 1996 Feb; 73(4):499-505. PubMed ID: 8595165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N.
    Wilson WR; Denny WA; Pullen SM; Thompson KM; Li AE; Patterson LH; Lee HH
    Br J Cancer Suppl; 1996 Jul; 27():S43-7. PubMed ID: 8763844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1.
    Nishida CR; Lee M; de Montellano PR
    Mol Pharmacol; 2010 Sep; 78(3):497-502. PubMed ID: 20566689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo.
    McKeown SR; Hejmadi MV; McIntyre IA; McAleer JJ; Patterson LH
    Br J Cancer; 1995 Jul; 72(1):76-81. PubMed ID: 7599069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AQ4N: a new approach to hypoxia-activated cancer chemotherapy.
    Patterson LH; McKeown SR
    Br J Cancer; 2000 Dec; 83(12):1589-93. PubMed ID: 11104551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study.
    Albertella MR; Loadman PM; Jones PH; Phillips RM; Rampling R; Burnet N; Alcock C; Anthoney A; Vjaters E; Dunk CR; Harris PA; Wong A; Lalani AS; Twelves CJ
    Clin Cancer Res; 2008 Feb; 14(4):1096-104. PubMed ID: 18281542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Examination of the distribution of the bioreductive drug AQ4N and its active metabolite AQ4 in solid tumours by imaging matrix-assisted laser desorption/ionisation mass spectrometry.
    Atkinson SJ; Loadman PM; Sutton C; Patterson LH; Clench MR
    Rapid Commun Mass Spectrom; 2007; 21(7):1271-6. PubMed ID: 17340571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent.
    Patterson LH; McKeown SR; Ruparelia K; Double JA; Bibby MC; Cole S; Stratford IJ
    Br J Cancer; 2000 Jun; 82(12):1984-90. PubMed ID: 10864207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts.
    Williams KJ; Albertella MR; Fitzpatrick B; Loadman PM; Shnyder SD; Chinje EC; Telfer BA; Dunk CR; Harris PA; Stratford IJ
    Mol Cancer Ther; 2009 Dec; 8(12):3266-75. PubMed ID: 19996276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N.
    McCarthy HO; Yakkundi A; McErlane V; Hughes CM; Keilty G; Murray M; Patterson LH; Hirst DG; McKeown SR; Robson T
    Cancer Gene Ther; 2003 Jan; 10(1):40-8. PubMed ID: 12489027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs).
    Denny WA; Wilson WR
    Cancer Metastasis Rev; 1993 Jun; 12(2):135-51. PubMed ID: 8375017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug.
    Raleigh SM; Wanogho E; Burke MD; McKeown SR; Patterson LH
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):763-7. PubMed ID: 9845092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aliphatic amine N-oxides of DNA binding agents as bioreductive drugs.
    Patterson LH; Craven MR; Fisher GR; Teesdale-Spittle P
    Oncol Res; 1994; 6(10-11):533-8. PubMed ID: 7620222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone.
    Trédan O; Garbens AB; Lalani AS; Tannock IF
    Cancer Res; 2009 Feb; 69(3):940-7. PubMed ID: 19176397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.